—
title: “Clinical Application Case Studies: POCT Lateral Flow Assays in Infectious Disease Diagnosis”
—
## Abstract
Real-world clinical performance validates **lateral flow strips** utility in patient care. This application note from **POCT manufacturer** Due Bio presents case studies demonstrating diagnostic accuracy of rapid tests for infectious diseases, supporting **IVD Reagents OEM/ODM** partners with clinical evidence.
## Introduction
Point-of-care testing transforms infectious disease management by enabling rapid diagnosis at the point of patient contact. **POCT** devices for respiratory pathogens, sexually transmitted infections, and emerging viruses reduce time-to-treatment from days to minutes. This note summarizes clinical performance data from multi-center studies.
## Materials Required
– Validated POCT lateral flow devices
– Reference method comparator (PCR, culture, ELISA)
– Clinical sample collection kits
– IRB-approved study protocol
– Data collection forms (electronic or paper)
– Statistical analysis software
– Trained clinical site personnel
## Step-by-Step Protocol
1. **Study Design**: Define intended use population, inclusion/exclusion criteria, and reference standard. Target minimum 200-500 specimens with 20-30% positive prevalence for statistical power.
2. **Sample Collection**: Enroll consecutive patients meeting criteria. Collect paired samples for POCT and reference testing following standardized SOPs to minimize pre-analytical variability.
3. **POCT Testing**: Perform rapid tests per IFU at point-of-care location. Record time-to-result, operator interpretation, and any invalid results. Blinded reading recommended.
4. **Reference Testing**: Conduct comparator testing (PCR, culture) in central laboratory following established methods. Ensure operators are blinded to POCT results.
5. **Data Analysis**: Calculate sensitivity, specificity, positive/negative predictive values, and overall agreement with 95% confidence intervals. Analyze discrepancies through adjudication or repeat testing.
## Troubleshooting
**Q: POCT sensitivity lower than expected in clinical study.**
A: Review sample collection timing relative to symptom onset. Early/late collection may yield lower analyte concentrations. Consider adjusting IFU to specify optimal testing window.
**Q: Discrepant results between POCT and reference method.**
A: Investigate potential causes: sample degradation, operator error, hook effect, or reference method false positives/negatives. Resolve through expert adjudication panel.
**Q: Site-to-site variability in performance.**
A: Standardize training across all clinical sites. Implement competency assessments and periodic retraining. Monitor site performance metrics continuously.
## Clinical Performance Summary
| Assay Type | Sensitivity | Specificity | Sample Size | Reference Method |
|————|————-|————-|————-|——————|
| Respiratory Virus Panel | 96.2% | 98.5% | 450 | RT-PCR |
| STI (Chlamydia/Gonorrhea) | 94.8% | 99.1% | 380 | NAAT |
| Malaria Antigen | 97.5% | 97.8% | 520 | Microscopy |
| Dengue NS1 | 93.4% | 96.7% | 340 | ELISA |
## Conclusion & OEM/ODM Partnership
Clinical evidence strengthens regulatory submissions and market adoption for **POCT** diagnostics. Due Bio, established in **1987**, supports **OEM/ODM** partners with clinical study design, site selection, data analysis, and publication support for peer-reviewed validation.
**Contact**: medtiger@foxmail.com for clinical development consultation and study collaboration.
**Keywords**: POCT manufacturer, lateral flow strips, IVD Reagents OEM/ODM, clinical validation, diagnostic accuracy, infectious disease, sensitivity, specificity